Recombinant Proteins Market Expected to Double to USD 5 Billion by 2032 with a CAGR of 7.6%
The Recombinant Proteins Market was valued at USD 2.5 billion in 2023 and is projected to reach USD 5.0 billion by 2032, growing at a CAGR of 7.6% from 2024 to 2032. This growth is driven by the rising prevalence of chronic diseases such as cancer, haemophilia, and sclerosis, alongside advancements in biologics and personalized medicine. The COVID-19 pandemic accelerated research and development in recombinant protein-based vaccines and therapeutics, transforming the biopharmaceutical landscape.